Ligand id: 7106

Name: acamprosate

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: acamprosate

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 4
Topological polar surface area 95.34
Molecular weight 181.04
XLogP -0.63
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Used alongside behavioural therapy to maintain alcohol abstinence in alcohol-dependent patients.
In 2014, the European Medicines Agency granted this drug orphan designation for the treatment of fragile X syndrome [2-3]. A Phase II/III clinical trial for this indication is underway (NCT01911455). Another Phase II/III clinical trial is recruiting patients to evaluate any benefit from acamprosate in autism disorder (NCT01813318).
Mechanism Of Action and Pharmacodynamic Effects
This drug acts as an antagonist of NMDA glutamate receptors and as a positive allosteric modulator of GABAA receptors. The glutaminergic hypothesis links this neurotransmitter system to alcohol dependence and withdrawal [1]. In addition, cortical and limbic arousal (sympathetic activation) levels are believed to be upregulated during alcohol withdrawal, as a 'bounce-back' response to alcohol-induced down-regulation of GABAA receptors. Acamprosate-potentiated GABAA activity helps to inhibit this elevated arousal. These two mechanisms appear to act together to provide the clinical benefits observed with use of this drug.
External links